DeCure for Microcephaly 21, primary, autosomal recessive
DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for microcephaly 21, primary, autosomal recessive — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleMicrocephaly 21, primary, autosomal recessive maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for microcephaly 21, primary, autosomal recessive is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
Autosomal recessive primary microcephaly (MCPH) is a genetically heterogeneous neurodevelopmental disorder defined by a significantly reduced head circumference present at birth and intellectual disability. Inconsistent features include hyperactivity, an expressive speech disorder, and epilepsy. All known genes implicated in MCPH are involved in monitoring centrosome integrity. Mutations in the human gene MCPH1, encoding microcephalin, cause primary microcephaly associated with a unique cellular phenotype of premature chromosome condensation. Microcephalin contains highly conserved BRCT domains and has fundamental roles in cell cycle, chromosome condensation, and DNA repair.
A PhD project reported generation of the first mouse model of impaired microcephalin function, which displayed the cellular phenotype of misregulated chromosome condensation. The same work mapped a candidate MCPH locus on chromosome 10q11.23-21.3, reported a functionally notable MCPH1 missense mutation (p.Trp75Arg) with a destabilising effect on the BRCT domain, and identified three mutations in the ASPM gene for MCPH disorder type five: p.Arg3096X, p.Arg1019X, and the first reported missense variant p.Lys1862Gln. These results provide further biological evidence for the essential roles of MCPH proteins in brain development.
A separate report described a large family with 13 affected members in three generations in which isolated microcephaly occurred without any other dysmorphic or neurological abnormalities. The pedigree confirmed autosomal dominant inheritance with incomplete penetrance, including one example of male-to-male transmission and a non-manifesting heterozygote resulting in a skipped generation. Considerable variation in phenotypic expression was noted. This isolated type of microcephaly should be distinguished from other dominantly inherited forms.
No drug treatments are mentioned in any of these abstracts. What is still missing is any clinical trial, any pharmacological intervention tested in patients or animal models, any funding directed toward drug development for MCPH, and any patient stratification strategy that might link specific genotypes to potential therapies.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Neuropediatrics · 2017 · 91 citations
Autosomal Recessive Primary Microcephaly (MCPH): An Update
AbstractAutosomal recessive primary microcephaly (MCPH; MicroCephaly Primary Hereditary) is a genetically heterogeneous neurodevelopmental disorder characterized by a significantly reduced head circumference present already at birth and intellectual disability. Inconsistent features include hyperactivity, an expressive speech disorder, and epilepsy. Here, we provide a brief overview on this rare disorder pertinent for clinicians.
AbstractA large family (13 affected members in three generations) is reported in which isolated microcephaly occurred without any other dysmorphic or neurological abnormalities. The family pedigree confirms the autosomal dominant mode of inheritance with incomplete penetrance, including one example of male to male transmission and the occurrence of a non-manifesting heterozygote resulting in a 'skipped generation'. There is considerable variation in the phenotypic expression of autosomal dominant microcephaly. This isolated (uncomplicated) type of microcephaly should be distinguished from other well defined, dominantly inherited forms of microcephaly.
Refubium (Universitätsbibliothek der Freien Universität Berlin) · 2013 · 0 citations · open access
Molecular genetic and cytogenetic analyses of autosomal recessive primary microcephaly (MCPH)
AbstractAutosomal recessive primary microcephaly (MCPH) is a neurodevelopment disorder, arising from a failure in embryonic neurogenesis, leading to microcephaly at birth. All known genes implicated in this disorder are involved in the monitoring of centrosome integrity. Mutations in the human gene MCPH1, encoding microcephalin protein, cause primary microcephaly associated with a unique cellular phenotype with premature chromosome condensation (PCC). Microcephalin contains highly conserved BRCT domains and has fundamental roles in cell cycle, chromosome condensation and DNA repair. The PhD project included generation of the first mouse model of impaired microcephalin function displaying the cellular phenotype of misregulated chromosome condensation, mapping a candidate MCPH locus on chromosome 10q11.23-21.3, reporting on a functionally notable MCPH1 missense mutation, p.Trp75Arg, with destabilizing effect on BRCT domain and identification of three mutations in the ASPM gene for MCPH disorder type five: p.Arg3096X, p.Arg1019X and the first reported missense variant p.Lys1862Gln. These results together provide further biological evidence for the MCPH proteins essential roles in brain development.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
